All News

exercise,group

ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment

d ACR

On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.

Read Article
Telemedicine

Video Telehealth Willingness Increased During Pandemic

d Jack Cush, MD

Americans’ willingness to use video telehealth has increased since the beginning of the COVID-19 pandemic, rising most sharply among Black Americans and people with less education, according to a new RAND Corporation study.

Read Article
infection pneumonia

Opportunistic Infections with JAK inhibitors in RA

d Jack Cush, MD

Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials, althou

Read Article
TB.EMimage.CDC_.jpg

2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections

d Jack Cush, MD

A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).

Read Article
Final countdown! We can't wait to see you in-person! #ACR22 https://t.co/nzf0mZJyxJ
Dr. John Cush RheumNow ( View Tweet)
Deprescribing in Older Adults w/ Rheumatic dz - When Less May Be More! Polypharmacy & multimorbidity are major problems in elderly. Deprescribing identifys problematic meds & tapering, stopping, D/C or withdrawing to maximize wellness https://t.co/vMTlp7SJjI https://t.co/sYkrjcouHM

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish study of Inflammatory bowel disease (IBD) pts w/ colorectal bx show that histological (aHR: 1.42 - 2.37) & clinical activity in IBD, especially UC (Not Crohns), were risk factors for preterm birth https://t.co/blGOjGxq70 https://t.co/xVvByFN2z1

Links:

Dr. John Cush RheumNow ( View Tweet)
Hear what KOLs are saying about #ACR22. We are featuring Drs: Michele Petri, Peter Nash, Artie Kavanaugh, Jack Cush. Follow us on Twitter and head to https://t.co/V10S4oVFsv for real-time coverage. https://t.co/u4GKfCYeTK

Links:

Dr. John Cush RheumNow ( View Tweet)
The spike protein of SARS-CoV-2 drives NLRP3 inflammasome activation (one of several reasons that patient may flare or activate after COVID-19 infection or vaccination?) https://t.co/92Z14bYaUD https://t.co/iEUSgPghtT

Links:

Dr. John Cush RheumNow ( View Tweet)
National Swedish Hip & Knee OA registry compared outcomes if pts seen in-person (F2F) or digitally (online) in 6946 pts - both groups improved at 3 mos; but digital pts had larger improvement at 3 mos (pain & Function) -- unknown if clinically meaningful https://t.co/yD4zAVpuhh https://t.co/IjqnTjXpbC

Links:

Dr. John Cush RheumNow ( View Tweet)
Undiagnosed RA During the Pandemic The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests. https://t.co/qEcEF8ukxm https://t.co/PcXAxrjT24

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of advances in bone biology leading to drug development (denosumab, romosuzumab, Burosumab), advances in Pagets and rickets and key regulatory molecules for bone remodeling, RANK, RANKL, OPG, & sclerostin https://t.co/CMMzIrZRUa https://t.co/ABhaHxP8y2

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Patricia Harkins, @DrTrishHarkins, is new to the #ACR22 RheumNow reporter team. From Dr. Harkins, "I am really looking forward to the new "Ignite sessions", as well as working with the Rheum Now Faculty for the first time!" Follow her for real-time #ACR22 coverage! https://t.co/dpDfNJs1V4
Dr. John Cush RheumNow ( View Tweet)
"I can't wait to see how the new format works: the poster hall, the SPARK talks, and to see a whole lot of people in person!" Follow Dr. David Liew, @drdavidliew, for real-time #ACR22 coverage! https://t.co/RBbLyqrBNT
Dr. John Cush RheumNow ( View Tweet)
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/tAaW41h7xS https://t.co/fn8sNbeslH

Links:

Dr. John Cush RheumNow ( View Tweet)
From the Crypt: Rheumatology Dead Word Cemetery Arthritis, Rheumatic Disease and Rheumatology cover a catalogue of ageless disorders w/decades, if not centuries, of history behind them.Enjoy our blog on retired Rheum sayings, as so decreed by RheumNow. https://t.co/WyBFEVa1h5 https://t.co/eE3HQ4N5Ia

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 New Drug Approvals Download today! https://t.co/nz91Ckw0AZ https://t.co/QieTvcqjcy

Links:

Dr. John Cush RheumNow ( View Tweet)
One week away! #ACR22 https://t.co/bvFCfFpQom
Dr. John Cush RheumNow ( View Tweet)
“I am looking forward to the ACR to hear about the ground-breaking results from basic science to the new treatments. I am delighted to be part of the RheumNow faculty covering the many topics from #ACR22. “ Follow Dr. Chan at @synovialjoints for real-time coverage of #ACR22. https://t.co/i6OZRHlBaE
Dr. John Cush RheumNow ( View Tweet)
New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes? This and more on the latest RheumNow podcast. https://t.co/4YBqHjI3VL https://t.co/g2pE72pyEk

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×